Renal Biomarkers Market

The renal biomarkers Market is anticipated to increase at a CAGR of 7.29% during the forecast period (2023-2028).

Market Overview

The renal biomarkers market is quickly expanding, owing to the rising prevalence of chronic kidney disease (CKD) and the increased need for early detection and treatment of kidney illnesses. The market segments are biomarker type, diagnostic technique, application, end-user, and geography.

The biomarker type section further divides into functional biomarkers, upregulated proteins, and other biomarkers. Functional biomarkers are those that allow the identification of renal damage in people with normal kidney function, as well as in people with chronic kidney disease, where the same injury would result in a considerable drop in functional biomarkers like Cr. Upregulated proteins are those that produce more in the context of renal damage. Other forms of biomarkers include genetic biomarkers, proteomic biomarkers, and epigenetic biomarkers.

Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, and BioMérieux are the market's leading contributors.

Market Drivers

The Prevalence of Chronic Kidney Disease (CKD) Is Rising

CKD is a degenerative disease that harms the kidneys and impairs their ability to filter waste from the blood. It is a significant global public health issue that affects an estimated 850 million people globally. The prevalence of CKD is rising due to a variety of reasons, including:

• Aging: As people get older, their chances of acquiring CKD rise. This is because the kidneys' function typically declines as we age.
• Obesity: Obesity is a significant risk factor for CKD. This is because being overweight puts a strain on the kidneys.
• Diabetes: It is a significant risk factor for CKD. This is because excessive blood sugar levels might harm the kidneys.
• Hypertension: It is a significant risk factor for CKD. This is because excessive blood pressure can harm the kidneys.

Rising Need for Early Kidney Disease Diagnosis and Treatment

Early detection and treatment of kidney illnesses is critical to preventing the development of the disease to end-stage renal disease (ESRD). ESRD is a potentially fatal disorder that necessitates dialysis or a kidney transplant. Renal biomarkers can help to detect kidney illnesses at an early stage when therapy is most successful.

Biomarker Technology Advancements

Biomarker technology has advanced significantly in recent years. These advancements have created novel kidney biomarkers that are more sensitive and specific than conventional biomarkers. This has allowed for earlier and more accurate diagnoses of renal disorders.

Cystatin C, for example, is a more sensitive and specific measure of renal function than creatinine. Creatinine is a common biomarker of kidney function. However, it is less sensitive than cystatin C. This suggests that cystatin C can detect renal disease sooner than creatinine.

Increasing Emphasis on Individualized Medicine

Personalized medicine is a healthcare method that considers individual patient factors such as genetics, lifestyle, and environment. Renal biomarkers provide the potential to tailor kidney disease therapy by identifying people who are more likely to react to certain therapies.

Albuminuria, for example, is a biomarker for kidney injury. Those with high albuminuria react better to some renal disease therapies than those with low albuminuria.

Initiatives from the Government

Governments all across the globe are investing in renal biomarker research and development. Renal biomarkers can potentially enhance kidney disease diagnosis, treatment, and prevention.

Market Opportunities

Chronic Kidney Disease (CKD) Is Becoming More Common

CKD is a serious global public health issue, impacting an estimated 850 million people globally. The prevalence of CKD is predicted to rise in the coming years due to various variables such as aging, obesity, diabetes, and hypertension. This rising frequency creates a large market potential for renal biomarkers.

Personalized Medicine is in High Demand

Personalized medicine is a healthcare method that considers unique patient characteristics such as genetics, lifestyle, and environment. Renal biomarkers provide the potential to tailor kidney disease therapy by identifying people who are more likely to react to certain therapies. As more healthcare providers implement customized medicine, this is significant business potential.

New Renal Biomarkers

Biomarker technology has advanced significantly in recent years. These breakthroughs have created novel renal biomarkers that are more sensitive and specific than conventional ones. This has allowed for earlier and more accurate diagnoses of kidney illnesses, offering a market potential for novel renal biomarkers.

The Growing Availability of Point-of-Care Testing

POCT tests blood or other body fluids at the point of care, such as at a doctor's office or a patient's home. POCT is becoming increasingly popular since it enables speedier illness detection and treatment. This opens up a market for renal biomarkers that can be employed in POCT scenarios.

The Rising Emphasis on Preventive Healthcare

As individuals become more aware of the value of early illness detection and treatment, there is a growing emphasis on preventive healthcare. This opens up a market for renal biomarkers, which may be used to test for kidney illnesses and track their course.

Market Challenges

The High Cost of Renal Biomarkers

Renal biomarkers might be costly, limiting their application in some contexts. A renal biomarker test, for example, can cost between $50 and $500. Because of the high expense, certain patients, particularly in impoverished countries, may struggle to purchase renal biomarkers.

The Absence of Standardized Testing Procedures

Because there is no defined testing protocol for renal biomarkers, comparing data from various laboratories might be problematic. This lack of consistency can also make interpreting data and treatment recommendations challenging.

The Need for Long-Term Data On Renal Biomarkers

Because there is no long-term evidence, assessing their usefulness can be challenging. This lack of evidence can also make developing guidelines for using renal biomarkers problematic.

False-Positive Findings

Renal biomarkers can occasionally provide false-positive results, which indicates that a patient may be mistakenly diagnosed with a kidney illness. This might result in patients receiving needless therapy and experiencing anxiety.

The Need for Further Research

There is still a need for additional studies on renal biomarkers, including research on developing novel biomarkers, the validation of current biomarkers, and the establishment of standardized testing protocols. This study is critical to ensuring kidney biomarkers' efficient and safe use.

Regional Coverage for Renal Biomarkers Market

North America

 It is the largest renal biomarker market, accounting for most worldwide. This is due to the region's high prevalence of chronic kidney disease (CKD). The United States is North America's largest market for renal biomarkers.

Europe

Europe is the world's second-largest market for renal biomarkers, accounting for a sizable portion of the total market. This is attributable to the region's high prevalence of CKD. Germany, France, and Italy are Europe's top markets for renal biomarkers.

Asia-Pacific

Asia-Pacific is the third-largest market for renal biomarkers, with the highest growth projected in the future years. This is attributable to the region's rising prevalence of CKD and the increased emphasis on individualized therapy. China and India are Asia-Pacific's major markets for renal biomarkers.

Latin America

Latin America is the fourth-largest market for renal biomarkers, with moderate growth projected in the next years. This is attributable to the region's rising prevalence of CKD and a greater emphasis on preventative healthcare. Brazil is Latin America's largest market for kidney biomarkers.

Middle East & Africa

The Middle East & Africa market for renal biomarkers is the smallest, but it is predicted to increase rapidly. This is attributable to the region's rising prevalence of CKD and the increased emphasis on individualized therapy. Saudi Arabia and South Africa are the Middle East and Africa's major markets for kidney biomarkers.

Company Recent Development

Thermo Fisher Scientific has released its new Kidney Function Assay (KFA) kit. The KFA kit is a point-of-care test measuring kidney function in people with chronic kidney disease (CKD).

Abbott Laboratories has announced the release of its new Kidney Function Test (KFT) kit. The KFT kit is a blood test that measures kidney function in CKD patients.

Siemens Healthineers AG has announced the availability of their new NephroSure test. The NephroSure assay is a blood test for diagnosing acute kidney injury (AKI).

F. Hoffmann-La Roche Ltd: F. Hoffmann-La Roche Ltd has introduced the Elecsys Kidney Function Test (KFT). The Elecsys KFT is a blood test that measures kidney function in CKD patients.

BioMérieux has announced the release of their new NephroCheck test. The NephroCheck assay is a urine test for diagnosing acute kidney injury (AKI).